Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Cost-Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease

Lee F. Allen, MD PhD, Kavita Aggarwal, PharmD, Michael Vredenburg, PhD, Christine Barnett, PhD, Deirdre Mladsi, BA, Ray Kim, MD

Blood (2019) 134 (Supplement_1): 3454.

https://doi.org/10.1182/blood-2019-131822

Published: 2019

Journal Articles

Long-Term Response Rates in Patients with Chronic Immune Thrombocytopenia Treated with Avatrombopag: Additional Analyses from a Phase 3 Study and Its Extension Phase

Hanny Al-Samkari, MD, Kavita Aggarwal, PharmD, Michael Vredenburg, PhD, Wei Tian, PhD, Lee F. Allen, MD PhD

Blood (2019) 134 (Supplement_1): 2356.

https://doi.org/10.1182/blood-2019-131215

Published: 2019

Journal Articles

Platelet Response to Avatrombopag in Patients with Chronic Immune Thrombocytopenia: Additional Analyses from a Phase 3 Study and Its Extension

Srikanth Nagalla, MBBS,MS, Michael Vredenburg, PhD, Wei Tian, PhD, Lee F. Allen, MD PhD

Blood (2019) 134 (Supplement_1): 1071.

https://doi.org/10.1182/blood-2019-130963

Published: 2019

Journal Articles

Absence of Plasma Gastric Biomarker Elevations with Chronic Dosing of Avatrombopag, a Novel Oral Thrombopoietin Receptor Agonist, in Patients with Chronic Immune Thrombocytopenia in Phase 3 Trials

James B. Bussel, MD, Lee F. Allen, MD PhD, Wei Tian, PhD, David J. Kuter, MD DPhil

Blood (2018) 132 (Supplement 1): 3740.

https://doi.org/10.1182/blood-2018-99-116873

Published: 2018

Journal Articles

Safe and Effective Treatment of Patients with Peripheral T-Cell Lymphoma (PTCL) with the Novel HDAC Inhibitor, Belinostat, in Combination with CHOP: Results of the Bel-CHOP Phase 1 Trial

Patrick B. Johnston, MD PhD, Amanda F. Cashen, MD, Petros G. Nikolinakos, MD, Anne W Beaven, MD, Stefan Klaus Barta, MDMRCP,MS, Gajanan Bhat, PhD, Tao Song, Mi Rim Choi, MD, Lee F. Allen, MD PhD, Sven de Vos, MD PhD, Yasuhiro Oki, MD, Changchun Deng, MDPhD, Francine M Foss, MD

Blood (2015) 126 (23): 253.

https://doi.org/10.1182/blood.V126.23.253.253

Published: 2015

Journal Articles

Safe and Effective Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) and Low Baseline Platelet Counts with Belinostat

Kerry J. Savage, MD MSc, Steven M. Horwitz, MD, Pier Luigi Zinzani, MD, PhD, Achiel Van Hoof, Sarit E. Assouline, MD, Gajanan Bhat, Mi Rim Choi, Lee F Allen, Dina Ben-Yehuda, MD, Wojciech Jurczak, Tamas Masszi, MD, Andrei R. Shustov, MD

Blood (2014) 124 (21): 3075.

https://doi.org/10.1182/blood.V124.21.3075.3075

Published: 2014

Journal Articles

Subsequent Hematopoietic Stem Cell Transplantation in Belinostat-Treated Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)

Andrei R. Shustov, MD, Haifa Kathrin Al-Ali, MD, Gerald Wulf, MD, Pamela Hsu, Mi Rim Choi, Lee F Allen, Otto J Visser, MD, Pierre Zachee, MD PhD, Steven M. Horwitz, MD

Blood (2014) 124 (21): 5438.

https://doi.org/10.1182/blood.V124.21.5438.5438

Published: 2014

Journal Articles

Safety and Efficacy Of Ferumoxytol For The Episodic Treatment Of Iron Deficiency Anemia In Patients With a History Of Unsatisfactory Oral Iron Therapy: Results Of a Phase III Open-Label, Six Month Extension Study

Saroj Vadhan-Raj, MD, Naomi V Dahl, Pharm.D., Gloria Lau, MSc, Kristine Bernard, Zhu Li, PhD, Pallabi De, PhD, Lee F. Allen, MD, PhD, William Strauss, M.D., F.A.C.C.

Blood (2013) 122 (21): 2201.

https://doi.org/10.1182/blood.V122.21.2201.2201

Published: 2013

Journal Articles

Ferumoxytol Treatment Demonstrates Significant Improvements in Fatigue and Health-Related Quality of Life in Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy

Saroj Vadhan Raj, Andrew Hsieh, William Strauss, M.D., F.A.C.C., Michael Stevenson, R.Ph., Ph.D., Kristine Bernard, Lee F. Allen, MD, PhD

Blood (2012) 120 (21): 478.

https://doi.org/10.1182/blood.V120.21.478.478

Published: 2012

Journal Articles

Ferumoxytol Treatment Results in Robust Hemoglobin Increases in Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy in a Phase III, Randomized, Placebo-Controlled Trial.

Saroj Vadhan Raj, Michael Cressman, David Ford, William Strauss, M.D., F.A.C.C., Gerri Poss, Kristine Bernard, Zhu Li, PhD, Lee F. Allen, MD, PhD

Blood (2012) 120 (21): 2098.

https://doi.org/10.1182/blood.V120.21.2098.2098

Published: 2012

Journal Articles

Potential New Treatment Option for Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy- Results of a Phase III, Randomized, Open-Label, Active-Controlled Trial of Ferumoxytol.

David Hetzel, Audrone Urboniene, Kristine Bernard, William Strauss, M.D., F.A.C.C., Michael Cressman, Zhu Li, PhD, Lee F. Allen, MD, PhD

Blood (2012) 120 (21): 2099.

https://doi.org/10.1182/blood.V120.21.2099.2099

Published: 2012

NARROW

Cost-Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease

Long-Term Response Rates in Patients with Chronic Immune Thrombocytopenia Treated with Avatrombopag: Additional Analyses from a Phase 3 Study and Its Extension Phase

Platelet Response to Avatrombopag in Patients with Chronic Immune Thrombocytopenia: Additional Analyses from a Phase 3 Study and Its Extension

Absence of Plasma Gastric Biomarker Elevations with Chronic Dosing of Avatrombopag, a Novel Oral Thrombopoietin Receptor Agonist, in Patients with Chronic Immune Thrombocytopenia in Phase 3 Trials

Safe and Effective Treatment of Patients with Peripheral T-Cell Lymphoma (PTCL) with the Novel HDAC Inhibitor, Belinostat, in Combination with CHOP: Results of the Bel-CHOP Phase 1 Trial

Safe and Effective Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) and Low Baseline Platelet Counts with Belinostat

Subsequent Hematopoietic Stem Cell Transplantation in Belinostat-Treated Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)

Safety and Efficacy Of Ferumoxytol For The Episodic Treatment Of Iron Deficiency Anemia In Patients With a History Of Unsatisfactory Oral Iron Therapy: Results Of a Phase III Open-Label, Six Month Extension Study

Ferumoxytol Treatment Demonstrates Significant Improvements in Fatigue and Health-Related Quality of Life in Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy

Ferumoxytol Treatment Results in Robust Hemoglobin Increases in Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy in a Phase III, Randomized, Placebo-Controlled Trial.

Potential New Treatment Option for Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy- Results of a Phase III, Randomized, Open-Label, Active-Controlled Trial of Ferumoxytol.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only